TB/FLU-04L

Phase of Development

No longer in development

Vaccine Platform

Viral Vector

Candidate Overview

Based on the attenuated influenza strain Flu NS106/ESAT-6_Ag85A expressing mycobacterial antigens Esat-6 and Ag85A.

Sponsor / Lead Developer: Research Institute for Biological Safety Problems (RIBSP)

Development partner(s): Smorodintsev Research Institute of Influenza (SRII)

Clinical Trials

COMPLETED TRIALS
Registry NumberNCT02501421
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Related Publications

  1. Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis (Drug Res (Stuttg), 2022)
  2. A New Intranasal Influenza Vector-Based Vaccine TB/FLU-04L Against Tuberculosis: Preclinical Safety Studies (Drug Res (Stuttg), 2022)

Source: Vaccine sponsor; ClinicalTrials.gov registry; Online search

Date Updated/Reviewed: 01-Jul-2022